Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardiff Oncology, Inc. (Nasdaq: CRDF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on PLK1 inhibition and its lead asset onvansertib, Cardiff Oncology uses filings such as Forms 10-K, 10-Q and 8-K to report its financial condition, clinical development progress and material corporate events.
In recent Form 8-K filings, Cardiff Oncology has furnished press releases covering quarterly financial results, business updates and positive data from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. These filings also reference presentation materials for clinical data updates and summarize key milestones in the onvansertib program. Other 8-Ks document outcomes of the annual meeting of stockholders, including director elections, auditor ratification, equity plan amendments and advisory votes on executive compensation.
Through its periodic reports, such as Form 10-K and Form 10-Q, Cardiff Oncology discusses research and development expenses, royalty revenues, cash and investment balances, and risk factors associated with clinical-stage oncology drug development. These documents outline the company’s dependence on successful clinical trials, regulatory approvals and access to capital, as well as competitive and operational risks.
On Stock Titan, each filing is accompanied by AI-powered summaries that highlight the most important points, helping readers quickly understand complex financial tables, clinical program descriptions and legal language. Users can follow new filings in near real time as they are posted to EDGAR and use this page to review Cardiff Oncology’s historical regulatory record, including information relevant to governance, compensation, capital structure and the progress of onvansertib across multiple cancer indications.
Cardiff Oncology, Inc. (CRDF) – Form 4 Overview
On 06/26/2025, Director Gary W. Pace received a grant of 40,565 stock options with an exercise price of $3.16 per share under the company’s equity compensation plan. The options expire on 06/26/2035. After the grant, Mr. Pace beneficially owns 187,539 derivative securities (options) in total. The Form 4, filed on 06/27/2025, reports no open-market purchases or sales of common stock, and the holdings are reported as Direct (D) ownership. This filing reflects routine director compensation rather than an investment decision.
Cardiff Oncology (Nasdaq:CRDF) filed a Form 8-K detailing the 26 June 2025 Annual Meeting vote results.
- All seven director nominees were elected with roughly 20.5-21.2 M votes in favor and no votes against.
- Shareholders ratified BDO USA, P.C. as the independent auditor for FY 2025 (36.3 M for, 1.2 M against, 1.1 M abstain).
- An amendment raising the 2021 Equity Incentive Plan’s share reserve to 12.15 M shares passed (16.9 M for, 5.0 M against).
- The advisory say-on-pay resolution was approved (18.9 M for, 2.6 M against).
No other material business or operational updates were disclosed.